[(R)-环丙基(苯基)甲基]胺 | 434307-26-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: [(R)-环丙基(苯基)甲基]胺
• 英文名称: (R)-cyclopropyl(phenyl)methanamine
• CAS: 434307-26-3
• 化学式: C₁₀H₁₃N
• 分子量: 147.22
• InChiKey: UCRSQPUGEDLYSH-JTQLQIEISA-N

物化性质

• 密度：
  1.082

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  3-[(4-ethoxy-1-oxo-1,2,5-thiadiazol-3-yl)amino]-2-hydroxy-N,N-dimethylbenzamide 、 [(R)-环丙基(苯基)甲基]胺 在 N,N-二异丙基乙胺 作用下， 以 甲醇 为溶剂， 生成 3-[[4-[[(R)-cyclopropyl(phenyl)methyl]amino]-1-oxo-1,2,5-thiadiazol-3-yl]amino]-2-hydroxy-N,N-dimethylbenzamide
  参考文献：
  名称：

  3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists

  摘要：

  A series of potent and selective 3,4-diamino-1,2,5-thiadiazoles were prepared and found to show excellent binding affinities towards CXCR2 receptor. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.027

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：EXITHERA PHARMACEUTICALS INC

  公开号：WO2018118705A1

  公开（公告）日：2018-06-28

  The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

  本发明提供了抑制因子XIa或激肽酶以及其药用盐和组合物的化合物。本发明还提供了使用这些化合物和组合物的方法。
• Novel compounds
  申请人：——

  公开号：US20040102633A1

  公开（公告）日：2004-05-27

  Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: wherein: R 1 is H or alkyl; R 2 is —R 8 R 9 ; R 8 is a single bond or alkyl, optionally substituted one or more times by hydroxy; R 9 is aryl or cycloalkyl or heteroaryl, optionally substituted one or more times by hydroxy, alkoxy, or alkoxyalkyl; R 3 is H or alkyl or cycloalkyl or cycloalkylalkyl, optionally substituted one or more times by hydroxy or by one or more fluorines; R 4 is —NR 10 R 11 ; R 10 and R 11 are independently selected from H or alkyl, or R 10 and R 11 together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic ring comprising 3-8 ring members, which heterocyclic ring is unsubstituted or is substituted one or more times by one or more substituents R 12 ; R 12 is oxo or —R 13 R 14 R 15 , wherein R 13 is a single bond or alkyl, R 14 is OC(O) or C(O)O, and R 15 is H or alkyl; R 5 is an alkyl, cycloalkyl, cycloalkylalkyl, aryl, or single or fused ring aromatic heterocyclic group, which group is unsubstituted or is substituted one or more times by one or more substituents selected from halo such as fluoro, alkyl or haloalkyl such as fluoroalkyl; R 6 represents H or up to three substituents independently selected from the list consisting of: alkyl, alkenyl, aryl, alkoxy or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, alkoxycarbonyl, haloalkyl such as trifluoromethyl, acyloxy, amino, mono- or di-alkylamino, alkoxyamido, alkoxycarboxylate or an esterified derivative thereof; R 7 is H or halo; a is 1-6; and any of R 1 , R 3 , R 5 , R 8 , R 9 , R 10 , R 11 and R 12 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  以下式（I）的某些化合物或其药学上可接受的盐或水合物： 其中： R1为H或烷基； R2为—R8R9； R8为单键或烷基，可以被羟基替代一次或多次； R9为芳基或环烷基或杂环烷基，可以被羟基、烷氧基或烷氧基烷基替代一次或多次； R3为H或烷基或环烷基或环烷基烷基，可以被羟基或一次或多次氟原子替代； R4为—NR10R11； R10和R11独立选择自H或烷基，或者R10和R11连同它们连接的氮原子形成一个由3-8个环成员组成的饱和或不饱和杂环，该杂环未被取代或被一个或多个取代基R12取代一次或多次； R12为氧代或—R13R14R15，其中R13为单键或烷基，R14为OC（O）或C（O）O，R15为H或烷基； R5为烷基、环烷基、环烷基烷基、芳基或单环或融合环芳基杂环基，该基未被取代或被一个或多个取代基选自卤素如氟、烷基或卤代烷基如氟代烷基取代一次或多次； R6代表H或最多三个独立选择自以下列表中的取代基：烷基、烯烃基、芳基、烷氧基或其羟基衍生物、羟基、卤素、硝基、氰基、羧基、羧胺基、磺胺基、烷氧羰基、卤代烷基如三氟甲基、酰氧基、氨基、单烷基或二烷基氨基、烷氧胺基、烷氧羧酸酯或其酯化衍生物； R7为H或卤素； a为1-6； 以及R1、R3、R5、R8、R9、R10、R11和R12中的任何一个可以选择性地被卤素、羟基、氨基、氰基、硝基、羧基或氧代基取代一次或多次； 制备这种化合物的过程，包括这种化合物的药物组合物以及这种化合物和组合物在医学中的应用。
• THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
  申请人：Biju J. Purakkattle

  公开号：US20080090823A1

  公开（公告）日：2008-04-17

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  本发明涉及的是一种新型的化合物，其结构式如下：其中包括Substituent A和Substituent B，其药学上可接受的盐和溶剂化合物。Substituent A的基团包括杂环芳基、芳基、杂环烷基、环烷基、炔基、烯基、氨基烷基、烷基或氨基。Substituent B的基团包括芳基和杂环芳基。本发明还涉及一种治疗趋化因子介导疾病的方法，例如癌症、血管生成、眼部血管生成性疾病、肺部疾病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和缺血再灌注损伤、疼痛（例如急性疼痛、急性和慢性炎症性疼痛和神经病理性疼痛），使用化合物IA的方法。
• Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070264230A1

  公开（公告）日：2007-11-15

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.

  揭示了具有以下结构的新化合物：以及其药物可接受的盐和溶剂化物。包括取代基A的基团的例子包括杂环芳基，芳基，杂环烷基，环烷基，炔基，烯基，氨基烷基，烷基或氨基。包括取代基B的基团的例子包括芳基和杂环芳基。此外，还揭示了使用式IA的化合物治疗趋化因子介导的疾病的方法，例如，癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化症，类风湿性关节炎，骨关节炎，中风和心脏再灌注损伤，急性疼痛，急性和慢性炎症性疼痛以及神经病理性疼痛。
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070021494A1

  公开（公告）日：2007-01-25

  There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  公开了以下化合物的公式或其药学上可接受的盐或溶剂，它们可用于治疗趋化因子介导的疾病，如急性和慢性炎症性疾病和癌症。